Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on June 19, 2017. The filing discloses significant changes to the company's executive leadership and Board of Directors, specifically the transition of the current CEO to Executive Chairman and the appointment of a new CEO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and corporate governance changes.
Material Changes
- Leadership Transition: Amarpreet S. Sawhney, Ph.D., will transition from President and CEO to Executive Chairman of the Board. He will continue as CEO until September 18, 2017, or the start date of the new CEO.
- New CEO Appointment: Antony C. Mattessich has been appointed as President and CEO, effective September 18, 2017, or a mutually agreed date prior to September 30, 2017.
- Board Composition: James Garvey resigned from the Board effective June 20, 2017. Antony C. Mattessich was elected to fill the vacancy as a Class I director effective June 20, 2017.
Compensation, Outlook, and Risks
Executive Compensation Details
- Dr. Sawhney (Executive Chairman): Minimum base salary adjusted to $281,209 per year. Eligible for an annual cash bonus of up to 55% of base salary. Initial term is one year, automatically renewable.
- Mr. Mattessich (New CEO):
- Minimum annual base salary of $550,000.
- One-time sign-on bonus of $250,000.
- Relocation reimbursement up to $250,000.
- Annual cash bonus eligibility of up to 60% of base salary (2017 bonus not pro-rated).
- Stock Option: Granted 590,000 shares at an exercise price of $10.94 per share. Vesting occurs over four years (25% on first anniversary, remainder monthly).
Severance and Contingencies
Mr. Mattessich's agreement includes clawback provisions for the sign-on bonus and relocation reimbursement if he does not commence employment by September 30, 2017, or terminates within one year for "cause" or without "good reason." Severance benefits include 12 months of base salary and health insurance for termination without cause or resignation for good reason. In the event of a "corporate change" followed by such termination within 12 months, benefits increase to 18 months of salary, 1.5x target bonus, and full acceleration of equity vesting.
Investor Verification Checklist
- Verify the exact commencement date of Mr. Mattessich's employment to confirm the vesting schedule of his stock options.
- Review the company's cash position to assess the impact of the $500,000 in immediate cash bonuses and relocation reimbursements for the new CEO.
- Monitor the transition period ending September 18, 2017, for any operational disruptions during the CEO handover.
- Confirm the status of the 590,000 stock options granted outside the 2014 Stock Incentive Plan and their impact on share dilution.